Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer

Survivorship Care Planning in Colorectal and Lung Cancer: A Feasibility Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01741636

Enrollment

Registered

2012-12-05

Start date

2013-01-31

Completion date

2013-12-31

Last updated

2013-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage I Rectal Cancer

Brief summary

Survivorship Care Planning may improve overall well-being and quality of life of colorectal and lung cancer survivors

Detailed description

PRIMARY OBJECTIVES: I. To test the feasibility and acceptability of an Advanced Practice Nurse (APN) driven Survivorship Care Planning (SCP) intervention for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) survivors. SECONDARY OBJECTIVES: I. Development of the infrastructure and strategy for a larger comparative intervention study. OUTLINE: Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.

Interventions

OTHEReducational intervention

Undergo Survivorship Care Planning

OTHERquestionnaire administration

Ancillary studies

PROCEDUREquality-of-life assessment

Ancillary studies

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathologically confirmed diagnosis of stage I, II, or III CRC or NSCLC * Able to read and understand English * Able to read and/or understand the study protocol requirements, and provide written informed consent * Diagnosis of CRC or NSCLC * Within three months of completing primary treatment (surgery, chemotherapy, radiation, or chemoradiation) * Without recurrent or new primary cancers

Design outcomes

Primary

Measure	Time frame	Description
Data collection protocols including who will administer the survey, timing of surveys, telephone interviews vs. face to face administration	2 months	—
Percentage of those who are qualified and agree to participate	2 months	—
Percentage of attrition based on number of patients who failed to complete the two-month study	2 months	Descriptive statistics will be presented on those who agree to participate and the proportion of those approached who agree to participate.
Total retention across the two month follow-up	2 months	Descriptive statistics will be presented on those who agree to participate and the proportion of those approached who agree to participate.
Cost implications including hiring and training of the research staff, development of study manuals and patient education materials, research staff time, intervention supplies, and other miscellaneous costs	2 months	—
Satisfaction with the timing, content, and delivery of the intervention	2 months	Quantitative and qualitative descriptive statistics will be analyzed.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026